Vertex Pharmaceuticals (NASDAQ: VRTX) is a growing pharmaceutical company with a robust cystic fibrosis (CF) business that generated nearly $10 billion in revenue last year. While there is still more room for the business to get bigger, Vertex is already at a sizable market cap of $100 billion. Does this stock have enough runway to generate significant returns and help you become a millionaire in the long run?

Vertex is more than just a CF company, and that's why many growth investors remain bullish on its prospects -- they know there are more growth catalysts out there. Vertex's growth opportunities take the company down multiple avenues, including a non-opioid pain medication that has shown promise in clinical trials.

VX-548 is a non-opioid treatment for pain which could be a game changer for the healthcare industry, giving patients a way to address pain with much less fear of getting addicted to opioids. The company plans to apply for regulatory approval this year. At its peak, VX-548 may generate $5 billion in annual revenue for Vertex.

Continue reading

Source Fool.com